Current State of Evidence and Practice of Prostate-Specific Membrane Antigen (Psma) Imaging Across the Prostate Cancer Clinical Landscape – Oncologist Perspective

Abstract

Prostate cancer (PC) is the most widespread malignancy in men worldwide and the third leading cause of cancer-related death. Accurate diagnostic and staging procedures are key for therapy success and personalized treatment in all stages of PC. Prostate cancer-specific positron emission tomography-computed tomography (PET/CT) is able to detect disease sites in both localized and recurrent PC, at serum levels of prostate specific antigen (PSA) that are lower compared with those detected by conventional imaging. Currently, the backbone of nuclear medicine staging in PC is based on prostate-specific membrane antigen (PSMA) PET/CT, given the numerous advantages of PSMA over other tracers used for PC molecular imaging. In this free-style narrative review, the historic perspective, literature, clinical utility, and practice patterns of PSMA PET/CT in PC are discussed and key points summarized for busy oncologists with an interest in PC.

Keywords

• PSMA
• Staging
• Restaging
• Biochemical failure
• Theranostics
• PET/CT